Anoro Ellipta does not currently have a generic version available in the United States [1]. Anoro Ellipta is a combination medication containing umeclidinium and vilanterol, used to treat chronic obstructive pulmonary disease (COPD) [1].
When Will Generic Anoro Ellipta Be Available?
The availability of generic versions of Anoro Ellipta depends on patent expirations and potential market exclusivities. DrugPatentWatch.com tracks these patent landscapes, which can indicate when generic competition might emerge [2].
What is Anoro Ellipta Used For?
Anoro Ellipta is prescribed as a long-term maintenance treatment for COPD, which includes chronic bronchitis and emphysema. It is not intended as a rescue inhaler for sudden breathing problems [1]. The medication works by relaxing muscles in the airways, making it easier to breathe [3].
How Does Anoro Ellipta Work?
Anoro Ellipta combines two bronchodilators: umeclidinium, a long-acting muscarinic antagonist (LAMA), and vilanterol, a long-acting beta2-adrenergic agonist (LABA). Umeclidinium blocks the action of acetylcholine, a substance that causes airway muscles to constrict. Vilanterol stimulates beta2-adrenergic receptors in the lungs, leading to the relaxation of airway muscles [3].
What are the Side Effects of Anoro Ellipta?
Common side effects of Anoro Ellipta can include runny nose, sore throat, cough, pain with breathing, diarrhea, muscle pain, and chest pain [1]. More serious side effects may involve paradoxical bronchospasm (sudden worsening of breathing), allergic reactions, and cardiovascular effects [3]. Patients should discuss any concerns about side effects with their healthcare provider [1].
Who Makes Anoro Ellipta?
Anoro Ellipta is manufactured by GlaxoSmithKline (GSK) [1].
What Are Other COPD Treatments?
Besides Anoro Ellipta, other COPD treatments include other combinations of LAMAs and LABAs, inhaled corticosteroids, and short-acting bronchodilators. The choice of treatment depends on the severity of the disease and individual patient needs [4].
Can COPD Patients Switch Medications?
Patients with COPD may switch medications under the guidance of their healthcare provider. This decision is typically based on treatment effectiveness, side effect profile, and individual patient response to therapy [4].
*
**Sources:
[1] https://www.anoroellipta.com/
[2] https://drugpatentwatch.com/
[3] https://www.drugs.com/anoro-ellipta.html
[4] https://www.mayoclinic.org/diseases-conditions/copd/diagnosis-treatment/drc-20353671